Results 1 to 10 of about 2,472,617 (310)

Association of community distress and risk of adverse events on the lung transplant waitlist [PDF]

open access: yesJHLT Open
Background: Socioeconomic disparities in lung transplantation outcomes have been well described, but little is known about the impact of community-level disparities amongst waitlisted patients. This study examines the relationship between community-level
Alan M. Jacob, MS   +21 more
doaj   +2 more sources

High-Antimicrobial Gallium-Doped Zinc Oxide Thin Films on Bio-Based Poly(Ethylene Furanoate) Substrates for Food Packaging Application

open access: yesMembranes, 2023
Thin films of gallium-doped zinc oxide (GZO), with a thickness of around fifty nanometers were deposited on bio-based poly(ethylene furanoate) (PEF) substrates by radio-frequency sputtering.
Chaoting Zhu   +4 more
doaj   +1 more source

Adverse events: an expensive and avoidable hospital problem

open access: yesAnnals of Medicine, 2022
Introduction Adverse healthcare-related events (AE) entail reduced patient safety. Estimating their frequency, characteristics, avoidability and impact is a means to identify targets for improvement in the quality of care.Methods This was a descriptive ...
Diego San Jose-Saras   +5 more
doaj   +1 more source

Bio-based poly(ethylene furanoate)/ZnO transparent thin films with improved water vapor barrier and antibacterial properties for food packaging application

open access: yesMaterials Research Express, 2022
Poly(ethylene furanoate) (PEF) biocomposite films incorporating zinc oxide nanoparticle (ZnO NPs) were prepared using a solvent casting method. The ZnO NPs were homogeneously dispersed within the PEF films with the aid of γ −aminopropyltriethoxylsilane ...
Chaoting Zhu   +3 more
doaj   +1 more source

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events

open access: yesPharmaceuticals, 2023
Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform/lichenoid ircAE phenotype.
Stephanie L. Gu   +6 more
doaj   +1 more source

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial

open access: yesTrials, 2020
Background Safety data is required to be collected in all clinical trials and can be separated into two types of data, adverse events and serious adverse events.
Elizabeth C. James   +4 more
doaj   +1 more source

Do Assets Help Families Cope With Adverse Events? [PDF]

open access: yes, 2009
Compares the extent to which families with liquid assets are better able to maintain their material well-being when adverse events affecting income such as job loss or illness occurs than families without assets.
Caroline Ratcliffe   +2 more
core   +2 more sources

Reducing preventable adverse events in obstetrics by improving interprofessional communication skills – Results of an intervention study

open access: yesBMC Pregnancy and Childbirth, 2023
Background Progress in medicine involves the structured analysis and communication of errors. Comparability between the individual disciplines is only possible to a limited extent and obstetrics plays a special role: the expectation of a self-determined ...
Beate Hüner   +7 more
doaj   +1 more source

Cosmetics utilization and associated adverse events: A community based cross-sectional study

open access: yesClinical Epidemiology and Global Health, 2023
Background: Cosmetics can enhance a person's perception of their beauty, but they can also be harmful. Despite a high incidence of adverse events, no study was conducted on cosmetics usage patterns and their associated adverse events at the community ...
Sweta Kumari   +3 more
doaj   +1 more source

Further Analyses of the Safety of Verubecestat in the Phase 3 EPOCH Trial of Mild-To-Moderate Alzheimer’s Disease [PDF]

open access: yes, 2019
Background: Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events.
Aisen, Paul S.   +12 more
core   +3 more sources

Home - About - Disclaimer - Privacy